Otonomy Appoints George Morrow to Board of Directors
April 30 2015 - 7:30AM
Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical
company focused on the development and commercialization of
innovative therapeutics for diseases and disorders of the inner and
middle ear, today announced the appointment of George J. Morrow to
the board of directors. Mr. Morrow brings more than 30 years of
experience in pharmaceutical commercial operations for leading
pharmaceutical companies including Amgen, GlaxoSmithKline and
Merck. From 2003 until his retirement in 2011, Mr. Morrow served as
executive vice president, global commercial operations at Amgen
where he was responsible for commercial and government affairs
activities across 50 countries including the United States.
"The knowledge and insights George has gained from decades of
experience leading commercial operations at top-tier pharmaceutical
companies will be invaluable for Otonomy as we prepare for
commercialization of AuriPro™ in the U.S. market in the first
quarter of 2016," said David A. Weber, Ph.D., president and CEO of
Otonomy. "Furthermore, I expect that George will make important
contributions related to the board's activities given his
significant current and former service as a director."
Mr. Morrow led global commercial operations for Amgen for nearly
a decade overseeing commercial and government affairs activities
across 50 countries, and continued to serve as a consultant to the
company following his retirement. Prior to his retirement Mr.
Morrow held the role of executive vice president, global commercial
operations, and prior to this position he was the executive vice
president of worldwide sales and marketing. During this time Amgen
transformed from a company with two products and $3.2 billion in
revenue to a multi-product company with $15 billion in revenue.
Prior to Amgen, Mr. Morrow held roles of increasing responsibility
involving commercial affairs at GlaxoSmithKline and its
subsidiaries for nearly a decade. Most recently he served as the
president and CEO for Glaxo Wellcome Inc., responsible for
commercial, manufacturing, finance, medical affairs, legal,
corporate and government affairs for U.S. operations. Prior to
Glaxo Wellcome, Mr. Morrow held marketing-related positions of
increasing responsibility at Merck.
Mr. Morrow currently serves on the board of directors of Vical
Incorporated and Align Technology, Inc. He previously served on the
board of directors of Safeway Inc., a food and drug retailer, and
Human Genome Sciences, Inc., a public biopharmaceutical development
company acquired by GlaxoSmithKline. Mr. Morrow obtained a master's
degree in business administration from Duke University, a master's
degree in biochemistry from Bryn Mawr College and a bachelor's
degree in chemistry from Southhampton College, Long Island
University.
In addition, Otonomy also announced that Brian Dovey, partner of
Domain Associates, and John McKearn, Ph.D., managing director of
RiverVest Venture Partners, will not continue as directors
following Otonomy's annual meeting of stockholders in June
2015.
"I would like to take this opportunity to express my great
appreciation for the support and guidance that both Brian and John
have provided to Otonomy during the past five years, a period of
significant growth and maturation for the company," added Dr.
Weber.
About Otonomy
Otonomy is a clinical-stage biopharmaceutical company focused on
the development and commercialization of innovative therapeutics
for diseases and disorders of the ear. Otonomy's proprietary
technology provides sustained exposure of drugs to the middle and
inner ear following a single intratympanic injection. Otonomy has
three product candidates in development. AuriPro™ is an antibiotic
that has completed Phase 3 clinical trials in pediatric patients
with middle ear effusion at the time of tympanostomy tube placement
surgery, and a New Drug Application for AuriPro in this indication
has been filed with the FDA. OTO-104 is a steroid that is in the
first of two pivotal clinical studies for the treatment of patients
with Ménière's disease. OTO-311 is an NMDA receptor antagonist in
development as a treatment for tinnitus. For additional information
please visit www.otonomy.com.
CONTACT: Media Inquiries
Canale Communications
Heidi Chokeir, Ph.D.
Vice President
619.849.5377
heidi@canalecomm.com
Investor Inquiries
Westwicke Partners
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From Jul 2023 to Jul 2024